MCRM
NVS icon

Midway Capital Research & Management’s Novartis NVS Stock Holding History

Midway Capital Research & Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9K Hold
363
– – 0.05% 72
2026
Q1 		$55.4K Buy
+363
New +$55.6K 0.05% 71

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Midway Capital Research & Management's NVS Position: Q2 2026 in Review

Midway Capital Research & Management held its Novartis (NVS) position steady in Q2 2026 at 363 shares worth $56.9K. The position accounts for 0.05% of the portfolio, ranked #72.

Midway Capital Research & Management first reported a position in NVS in Q1 2026 and has held it in 2 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Midway Capital Research & Management held 363 shares of Novartis worth $56.9K as of Q2 2026.
  • Midway Capital Research & Management left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.05% of Midway Capital Research & Management's portfolio in Q2 2026, its #72 holding.
  • Midway Capital Research & Management first reported a position in Novartis in Q1 2026 and has held it in 2 quarters since.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Midway Capital Research & Management's 13F filing for Q2 2026, filed 14 Jul 2026.